JAK2 and acute lymphoblastic leukemia: Consistent with this principle, ruxolitinib has only exhibited a low efficacy in PDX models of CRLF2r/JAK2-mutant ALL, despite reductions in peripheral blood and splenic blast counts (Maude et al., 2012).